Ridgestone

Ridgestone Oncology is a biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company specifically targets the AP-1 (Activator Protein-1) transcription factor, a master regulator of gene expression involved in tumor progression, metastasis, and immune evasion. Ridgestone's lead programs are designed to inhibit the JNK/c-Jun signaling pathway to overcome resistance to current standards of care in various solid tumors. Based in South San Francisco, the company utilizes a specialized platform to identify potent and selective inhibitors of transcription factor complexes that were previously considered undruggable.